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1 
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2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The additive hydroxy-analogue of selenomethionine consists of synthetic R,S-2-hydroxy-4-methylselenobutanoic 
acid (HMSeBA) and is intended to be used as a source of the essential trace element selenium for all animal 
species/categories. Based on data from tolerance studies in chickens and turkeys for fattening and piglets, the 
additive is considered as safe for all species/categories up to the maximum authorised total selenium level in 
complete feed. After being absorbed, HMSeBA is metabolised to selenomethionine; consequently, no residues of 
the compound itself occur in animal tissues and products. Compared with inorganic selenium sources, the use of 
HMSeBA in animal nutrition would result in a similar increase in selenium deposition in animal tissues/products 
as that resulting from selenised yeast. To ensure consumer safety from consumption of food originating from 
animals supplemented with HMSeBA, the FEEDAP Panel concluded that selenium supplementation from the 
additive should not exceed a maximum of 0.2 mg Se/kg complete feed. The additive should be regarded as an 
eye irritant, but should not be classified as skin irritant or skin sensitiser. Inhalation exposure poses a hazard to 
users; the FEEDAP Panel concludes, therefore, that the formulation and conditions of use of the solid form of 
the  additive  should  minimise  user  exposure  by  inhalation.  The  use  of  HMSeBA  in  feed  does  not  pose  an 
additional risk to the environment, compared to other sources of selenium for which it will substitute, as long as 
the maximum authorised content in feedingstuffs is not exceeded. Based on the response of plasma glutathione 
peroxidase  activity  and  the  plasma/liver  concentration  of  selenium  in  chickens  for  fattening  and  pigs  for 
fattening,  the  FEEDAP  Panel  considers  that  HMSeBA  is  an  efficaceous  source  of  selenium  for  all  animal 
species/categories. HMSeBA does not modify the quality of meat as measured by physico-chemical properties. 
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SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and 
efficacy of the hydroxy-analogue of selenomethionine (HMSeBA) as feed additive for all species. The 
additive is intended to be used as a source of the essential trace element selenium in animal nutrition. 
Data from tolerance studies on chickens and turkeys for fattening and piglets showed that the additive 
HMSeBA is a safe selenium source when used up to the maximum authorised total selenium content 
in  complete  feed.  A  safety  margin  of  ten  was  identified.  Provided the  maximum  authorised  total 
selenium content in complete feed is not exceeded, the use of  HMSeBA as a selenium source is 
considered to be safe for all animal species/categories. 
Based on a toxicology testing package (acute toxicity, genotoxicity in vitro and in vivo, repeated dose 
toxicity)  it  is concluded  that  HMSeBA  does not elicit adverse  unexpected  effects  for  a  selenium 
compound. After being absorbed, HMSeBA is metabolised to selenomethionine; consequently, no 
residues  of  the  compound  itself  occur  in  animal  tissues  and  products.  Compared  with  inorganic 
selenium  sources,  the  use  of  HMSeBA  in  animal  nutrition  would  result  in  a  similar  increase  in 
selenium  deposition  in  animal  tissues/products  as  that  resulting  from  selenised  yeast.  To  ensure 
consumer safety from consumption of food originating from animals fed diets containing HMSeBA, 
the FEEDAP Panel concludes that dietary selenium supplementation from the additive should not 
exceed a maximum of 0.2 mg Se/kg complete feed.  
The additive should be regarded as an eye irritant, but should not be classified as skin irritant or skin 
sensitiser. Inhalation exposure poses a hazard to users; the FEEDAP Panel concludes, therefore, that 
the formulation and conditions of use of the solid form of the additive should minimise user exposure 
by inhalation. 
The use of HMSeBA in feed does not pose an additional risk to the environment, compared with other 
sources  of  selenium  for  which  it  will  substitute,  as  long  as  the  maximum  authorised  content  in 
feedingstuffs is not exceeded. 
Studies in chickens for fattening and pigs for fattening showed an increased plasma/liver selenium 
level and plasma glutathione peroxidase activity in response to feed supplementation with HMSeBA. 
Therefore, the FEEDAP Panel concludes that HMSeBA is an efficacious source of the essential trace 
element selenium for animal nutrition. The use of the additive does not modify the quality of meat as 
measured by physico-chemical properties.   Hydroxy-analogue of selenomethionine (HMSeBA) for all species 
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BACKGROUND 
Regulation  (EC)  No  1831/2003
4  establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7.  
The  European  Com mission  received  a  request from  the  company  ADISSEO  France  SAS
5  for 
authorisation of the product hydroxy-analogue of selenomethionine, when used as a feed additive for 
all animal  species (category:  nutritional additives; functional group: compounds of trace elements) 
under the conditions mentioned in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application to the European Food Safety Authority (EFSA) as an application under Article 4(1) 
(authorisation of  a feed additive or new use of a  feed additive).  EFSA received directly from the 
applicant  the  technical  dossier  in  support  of  this  application.
6  According  to  Article  8  of  that 
Regulation, EFSA, after verifying the particulars and documents submitted by the  applicant, shall 
undertake an assessment in order to determine whether the feed additive complies with the conditions 
laid down in Article 5. The particulars and documents in support of the application were considered 
valid by EFSA as of 21 February 2012.  
Two forms of inorganic selenium, sodium selenite and sodium selenate, are authorised in the European 
Union (EU) as source of the essential trace element selenium, under Directive 70/524/EEC.
7
 Organic 
forms of selenium produced by Saccharomyces cerevisiae CNCM I-3060, S. cerevisiae NCYC R397 
and S. cerevisiae CNCM I-3399 are authorised in the EU as trace element under Regulation (EC) No 
1831/2003.
8,9,10 These latter authorisations have been granted following corresponding EFSA opinions 
(EFSA 2006a, 2006b, 2009a). Two additional opinions on the safety and efficacy of selenium in the 
form  of  organic  compounds  produced  by  the  selenium-enriched  yeast  S.  cerevisiae  NCYC  R645 
(EFSA, 2011a) and NCYC R646 (EFSA, 2012a) for all animal species were delivered by the FEEDAP 
Panel Another opinion on the safety and efficacy of Sel-Plex
® (organic form of selenium produced by 
Saccharomyces cerevisiae CNCM I-3060) when used as zootechnical feed additive was adopted by 
the FEEDAP Panel (EFSA, 2011b).  
TERMS OF REFERENCE  
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animal(s), consumer, user and the environment and the efficacy of the product 
hydroxy-analogue of selenomethionine, when used under the conditions described in Table 1. 
                                                       
4   Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
5   ADISSEO France S.A.S. Immeuble Antony Parc II, 10 place du Général de Gaulle. 92160 Anthony. France. 
6   EFSA Dossier reference: FAD-2011-0044. 
7  List of the authorised additives in feedingstuffs published in application of Article 9t (b) of Council Directive 70/524/EEC 
concerning additives in feedingstuffs. OJ C 50, 25.2.2004, p. 1. 
8  Commission Regulation (EC) No 1750/2006 of 27 November 2006 concerning the authorisation of selenomethionine as a 
feed additive. OJ L 330, 28.11.2006, p. 9. 
9  Commission Regulation (EC) No 634/2007 of 7 June 2007 concerning the authorisation of selenomethionine produced by 
Saccharomyces cerevisiae NCYC R397 as a feed additive. OJ L 146, 08.06.2007, p. 14. 
10   Commission Regulation (EC) No 900/2009 of 25 September 2009 concerning the authorisation of selenomethionine 
produced by Saccharomyces cerevisiae CNCM I-3399 as a feed additive. OJ L 256, 29.09.2009, p. 12. Hydroxy-analogue of selenomethionine (HMSeBA) for all species 
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Table 1:   Description and conditions of use of the additive as proposed by the applicant  
Additive  
Selenium mainly represented by R,S-2-hydroxy-4-methylselenobutanoic 
acid (or HMSeBA) and other Se-based components 
Registration number/EC 
No/No (if appropriate)  3b8.xx 
Category(-ies) of additive  3. Nutritional additive 
Functional group(s) of additive  b. Compounds of trace elements 
 
Description 
Composition, description  Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Preparation, solid or liquid, with a maximum 
of 2.4% of selenium mainly represented by 
R,S-2-hydroxy-4-methylselenobutanoic acid 
(or HMSeBA) and other Se-based components 
(HMSeBA oligomers: dimers) on carrier 
Not 
appropriate 
Complies with 
EU law on 
undesirable 
substances 
- Zeeman graphite furnace 
atomic absorption 
spectrometry (AAS) or 
hydride AAS  
- Inductively coupled 
plasma mass spectrometry 
(ICP-MS) 
 
Trade name (if appropriate)  Selisseo 
Name of the holder of authorisation (if appropriate)  ADISSEO France SAS 
 
Conditions of use 
Species  or 
category  of 
animal 
Maximum 
Age 
Minimum 
content  Maximum content  Withdrawal 
period 
(if 
appropriate)  mg/kg of complete feedingstuffs 
All animal species 
or categories 
Not 
appropriate 
Not 
appropriate 
0.5 mg Se (total)/kg of complete 
feedingstuffs with a moisture content of 12% 
or  
0.25 mg Se (total)/litre of water of drinking 
Not 
appropriate 
 
Other provisions and additional requirements for the labeling 
Specific conditions or 
restrictions for use (if 
appropriate) 
The additive shall be incorporated into feed in form of a premixture 
Specific conditions or 
restrictions for handling (if 
appropriate) 
For user safety: breathing protection, safety glasses and gloves should be worn 
during handling 
Post-market monitoring  
(if appropriate) 
ADISSEO France SAS will conduct post-marketing monitoring in compliance 
with EU law on feed hygiene, namely by use of HACCP and Traceability 
systems,  and  formal  monitoring  of  customer  feedback  through  product  or 
service complaints. 
Specific conditions for use 
in complementary 
feedingstuffs  
(if appropriate) 
- The selenium feed additive is given continuously during animal rearing. 
- To supply selenium in final feeds within EU legal limits. 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue  Species or category of animal  Target tissue(s) or food 
products 
Maximum content in 
tissues 
Not relevant  Not relevant  Not relevant  Not relevant Hydroxy-analogue of selenomethionine (HMSeBA) for all species 
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ASSESSMENT 
1.  Introduction  
The  additive  consists  of  5 %  R,S-2-hydroxy-4-methylselenobutanoic  acid  (HMSeBA,  hydroxy-
analogue of selenomethionine) and 95 % carrier. The application under assessment is for the use of 
HMSeBA in feed and water for drinking for all animal species as source of the essential trace element 
selenium.  
The  biological  role  of  selenium  and  its  deficiency  and  toxicity  symptoms  in  farm  animals  were 
described in a previous opinion of the FEEDAP Panel (EFSA, 2006a). Selenium is a trace element, 
which  is  essential  for  vertebrates  and  is  involved  in  a  series  of  vital  metabolic  functions  (e.g. 
prevention  of  oxidative  stress,  proper  thyroid  function,  maintenance  of  cellular  redox  status, 
immunocompetence,  detoxification  of  heavy  metals  and  xenobiotics).  To  the  knowledge  of  the 
FEEDAP Panel, there is no additional relevant information that may lead it to reconsider its previous 
opinion.  
Since the selenium content of grain and forages is generally low in most European countries, livestock 
is routinely  supplied  with  extra  dietary  selenium  in  order to  avoid the  consequences  of selenium 
deficiency. 
For a similar product, L-selenomethionine, an opinion for use in food supplements has been produced 
by the EFSA‘s Panel on Food Additives and Nutrient Sources added to Food (EFSA, 2009b). L-
selenomethionine is authorised by Commission Regulation (EC) No 1170/2009
11 as mineral which 
may be used in the manufacture of food supplements. 
2.  Characterisation  
2.1.  Identity of the additive  
The additive is intended to be marketed in two forms: solid and liquid.  
The solid form of the additive consists of 5 % HMSeBA and 95 % carriers, containing by specification 
1.8 % to 2.4 % selenium. Carboxymethylcellulose, aluminosilicate, colloidal silica, cellulose, calcium 
carbonate and starch can be used as carriers; these compounds are already authorised as additives or 
are  feed  materials  in  the  European  Union.  The  analysis  of  five  batches  of  the  additive,  each 
manufactured with a different HMSeBA lot, showed mean HMSeBA and selenium contents of 5.1 % 
(range 5.0 5.1 %) and 2.0 % (range: 1.9 2.1 %), respectively.
12  
The liquid form of  the additive consists of 5 % HMSeBA diluted in distilled water, with the same 
specification for selenium content as the solid additive. The mean HMSeBA and selenium contents in 
five analysed batches were 5.1 % (range 5.0 5.1 %) and 2.1 % (range 1.9 2.4 %), respectively.
13  
2.2.  Impurities 
Both forms of the additive (three batches each) were analysed for heavy metals, arsenic,  fluorine, 
dioxins and the sum of dioxins and dioxin-like polychlorinated biphenyls (PCBs).
14 All values were 
compliant with EU legislation.
15 Lithium (three batches of the solid form)  concentration was in the 
                                                       
11   Commission Regulation (EC) No 1170/2009 of 30 November 2009 amending Directive 2002/46/EC of the European 
Parliament and of Council and Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards 
the lists of vitamin and minerals and their forms that can be added to foods, including food supplements. OJ L 314, 
1.12.2009, p. 36. 
12   Technical Dossier/Section II/Annex 2.1.5. Technical Dossier/Supplementary Information/Annex i-1 and Annex v-4. 
13   Technical Dossier/Supplementary Information/Annex v-1. 
14   Technical Dossier/Section II/Annex 2.1.6. Technical Dossier/Supplementary Information/Annex v-3. 
15   Directive 2002/32/EC of the European Parliament and of the Council of 7 May 2002 on undesirable substances in animal 
feed—Council statement. OJ L 140, 30.5.2002, p. 10. Hydroxy-analogue of selenomethionine (HMSeBA) for all species 
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range 3.5 5.0 mg/kg, which is not considered of any concern.
16 Microbial contamination was also 
studied in three batches of each form of the additive and found to be virtually absent (bacteria, yeasts 
and moulds < 5 CFU/g solid additive, < 1 CFU/g liquid additive;   Salmonella  absent  in  25  g  of 
product).
17 Monitoring of residual solvents originating from the synthesis of HMSeBA shows them to 
be below the  limit of detection  (LOD; 3.0 mg/kg)  for  tetrahydrofuran, diethoxymethane and di -
isopropylether, and 35 mg/kg for methylcyclohexane; the Veterinary International Cooperation on 
Harmonization  ( VICH)  Guideline  for  residual  solvents  classifies  tetrahydrofuran  and 
methylcyclohexane as "Class II solvents, Solvents to be limited", with concentration limits of 720 and 
1180 mg/kg respectively (VICH, 2011). Control methods are in place.  
2.3.  Physical state of the final formulations 
The solid form of additive is a white, odourless powder, with a bulk density of 352 kg/m
3.
18 Analysis 
of the particle size distribution by laser diffraction in three batches showed that 3.6 % of particles were 
< 10 µm in diameter (range 3.5 3.7 %), 21.9 % < 50 µm (range 20.1 23.2 %) and 42.5 % < 100 µm 
(range 40.5 43.1 %); the mean particle diameter ranged from 114 to 123 µm.
19 The dusting potential, 
measured by the Stauber –Heubach  method,  ranged  from  4.4  to  5.9 g/m
3  for  six  batches.
20  The 
selenium concentration in the dust amounted 9–11 mg/g, corresponding to about half of the selenium 
level in the additive.
21 
The liquid form of the additive is of pale-yellow colour and odourless. HMSeBA is highly soluble in 
water (> 491 g/L at 20 ºC).
22  
2.4.  Characterisation of the hydroxy-analogue of selenomethionine  
Selenium is considered to be the active substance of HMSeBA. More than 99 % of total selenium in 
the additive is in the form of HMSeBA and related selenocompounds. 
The principal selenocompound of the additive (providing >98 % of total selenium) is R,S-2-hydroxy-
4-methylselenobutanoic acid
23 (Chemical Abstracts Service (CAS) number 873660 -49-2; molecular 
weight 197.09 Daltons). The molecular formula is C5H10O3Se, with a theoretical content of selenium 
of 40.1 %. The identity of HMSeBA was confirmed by measuring its UV spectrum, which showed 
maximum  absorbance  at  220 nm,  and  by  structural  analysis  of  its 
1H  and 
13C  nuclear  magnetic 
resonance (NMR) spectra, infra-red spectrum and mass spectrum. The molecular structure is shown in 
Figure 1. 
 
 
 
 
Figure 1:   Molecular structure of HMSeBA 
                                                       
16   Technical Dossier/Supplementary Information/Annex iv-2. 
17   Technical Dossier/Section II/Annex 2.1.8. Technical Dossier/Supplementary Information/Annex v-5. 
18   Technical Dossier/Section II/Annex 2-1-12. 
19   Technical Dossier/Section II/Annex 2-1-11. 
20   Technical Dossier/Section II/Annex 2-1-13. 
21   Technical Dossier/Supplementary Information/Annex viii-2. 
22   Technical Dossier/Section II/Annex 2-2-4. 
23   Other names are hydroxy-analogue of selenomethionine, D,L-2-hydroxy-4-(methylseleno)-butanoic acid, α-hydroxy-γ-
methylseleno-butanoic acid, γ-methylseleno-α-hydroxybutanoic acid, R,S-2-hydroxy-4-(methylseleno)-butyric acid, D,L-2-
hydroxy-4-(methylseleno)-butyric acid, α-hydroxy-γ-methylseleno-butyric acid and γ-methylseleno-α-hydroxybutyric acid. Hydroxy-analogue of selenomethionine (HMSeBA) for all species 
 
EFSA Journal 2013;11(1):3046  8 
HMSeBA is a free-flowing, pale yellow odourless powder. Its melting and boiling points are 48.3 and 
245.3 
oC, respectively and the solubility in water is > 491 g/L at 20 ºC.  
High-performance liquid chromatographic (HPLC) analysis of six batches of HMSeBA showed a 
mean HMSeBA content of 98.9 % (range 98.7–99.3 %) with a mean total selenium level of 39.5 % 
(range 36.4–40.7 %).
24 In another five batches, the mean HMSeBA content was 99.0  % (range 98.8–
99.1 %)
25 and the mean total selenium level was 40.0 % (range 38.9–41.2 %).
26 The HMSeBA dimer 
(C10H18O5Se2) content was 0.3 % (range 0.2–0.4 %).
27 In five batches, the concentrations of two other 
selenocompounds, C8H14O6Se (molecular weight 286) and C8H14O6Se2 (molecular weight 366), were 
0.11 % (range 0.02–0.2 %) and 0.17 % (range 0.1–0.2 %),
28 respectively. Inorganic tetravalent and 
hexavalent selenium were below the limit of quantification (LOQ; 50 mg/kg).
29 
The residual solvents  (tetrahydrofuran, diethoxymethane, di-isopropylether and methylcyclohexane) 
and lithium (used for the synthesis of HMSeBA)  were analysed in three batches of HMSeBA.
30 The 
concentrations found (both tetrahydrofuran and diethoxymethane < LOD 3 mg/kg; di-isopropylether ≤ 
2.9 mg/kg; methylcyclohexane ≤ 8.8 mg/kg and Li ≤ 74 mg/kg) do not raise concerns considering the 
20-fold dilution in the blended additive. For both tetrahydrofuran and methylcyclohexane, listed in the 
VICH Guidelines, these analysed values are below the concentration limits set (720 and 1180 mg/kg, 
respectively) (VICH, 2011). 
2.5.  Manufacturing process 
The synthesis of HMSeBA involves seven steps. It starts with the reaction of methyllithium with 
selenium in the diethoxymethane and tetrahydrofuran solvents yielding methylselenolithium. After 
adding R,S-2-hydroxybutyrolactone the lithium salt of the 2-hydroxy-4-methylselenobutanoic acid is 
formed, acidified with sulphuric acid, extracted and concentrated in di-isopropylether solution. In the 
next  step,  the  R,S-2-hydroxy-4-methylselenobutanoic  acid  is  isolated  as  an  off-white  solid  by 
crystallisation  and  precipitated  in  a  mixture  of  di-isopropylether/methylcyclohexane,  filtered  and 
dried. Residual solvents are volatile and eliminated during the drying phase (under vacuum). Control 
measures  are  in  place  and  the  material  safety  data  sheets  of  each  material  used  in  synthesis  of 
HMSeBA are enclosed to the technical documentation. 
The solid form of the additive is manufactured by spraying a 40 % solution of HMSeBA on a carrier 
(e.g. silica) and mixing; the final product is sealed in aluminium bags with an internal wall of low 
density polyethylene. The liquid form of additive is manufactured by dissolving solid HMSeBA in 
distilled water (5 % solution).  
Control measures are in place (heavy metals, arsenic, dioxins and dioxin-like PCBs in carrier). 
2.6.  Physico-chemical and technological properties of additive 
2.6.1.  Stability 
The applicant provided studies based on analysis of HMSeBA and total selenium.  
Samples of three batches of the solid form of additive (in total, 15 sealed, low-density polyethylene 
pouches, each containing 2 g of additive) were stored in the dark and exposed to both normal (20 ºC, 
60 % relative humidity (RH)) and accelerated conditions (30 ºC, 65 % RH) for 12 months; one of the 
batches was stored for up to 18 months.
31 The recovery of HMSeBA after 12 months at normal and 
                                                       
24   Technical Dossier/Section II/Annex 2-2-1. 
25   Technical Dossier/Supplementary Information/Annex iii-2. 
26   Technical Dossier/Supplementary Information/Annex iii-3. 
27   Technical Dossier/Supplementary Information/Annex iii-1. 
28   Technical Dossier/Supplementary Information/Annex iii-2. 
29   Technical Dossier/Supplementary Information/Annex iii-3. 
30   Technical Dossier/Supplementary Information/Annex iv-1. 
31   Technical Dossier/Section II/Annex 2-4-3. Hydroxy-analogue of selenomethionine (HMSeBA) for all species 
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accelerated  conditions  was  91  and  80 %,  respectively;  the  batch  stored  for  18  months  showed 
recoveries of HMSeBA under normal and accelerated conditions of 89 and 78 %, respectively. In 
another ongoing study with three batches of the solid form, the available data after storage for up to 
three months showed recovery of the sum of HMSeBA and other Se-based components (monomer and 
dimers) under normal and accelerated conditions of 98 and 97 %, respectively.
32 
Stability studies  were provided for  the solid form of  the additive in premixtures  (for chickens for 
fattening, laying hens, turkeys and piglets)
33 and complete feeds (for chickens for fattening and piglets 
and dairy cows)
34 reporting only total selenium levels. The stability of  the additive to pelleting was 
also addressed only by analytical data on total selenium content.
35  
A study of stability of the liquid form during 48 hours was provided, however only analytical data on 
total selenium were submitted.
36 Data supporting stability of  HMSeBA in water for drinking at the 
proposed supplementation levels were not provided. 
The FEEDAP Panel notes that, in principle, analytical data on total selenium per se do not provide full 
evidence of the stability of an additive based on an organic selenium compound. The Panel also notes 
that  HMSeBA  is  an  analogue  of  amino  acid  and,  therefore,  not  expected  to  dissociate.  In  dry 
premixtures/feed  the  selenium-containing  hydroxy-analogue  of  methionine  is  expected  to  behave 
similarly to the sulphur-containing hydroxy-analogue of methionine, which has an established stability 
in feed.  
2.6.2.  Homogeneity 
A  complete  feed  for  laying  hens  (based  on  wheat  and  soybean  meal)  was  supplemented  via  a 
premixture with selenium from the solid form of the additive (one batch) in order to obtain its final 
intended level of 0.3 mg/kg total feed.
37 The selenium level analysed in ten feed subsamples showed a 
coefficient of variation (CV) of 10 %.  
In complete feed for pigs for fattening supplemented via premixture with 0.3 mg Se/kg from the solid 
form of the additive (one batch), the analysis of ten subsamples showed a CV for selenium distribution 
of 6.5 %.
38 In a tolerance trial on piglets, the complete feed was supplemented with 5  mg Se/kg (10-
fold higher than the maximum authorised selenium content in feed) from the solid form of the additive 
(one batch) via a premixture; the analysed selenium levels in ten subsamples of feed showed a CV of 
3.8 %.
39  
The selenium analysis of ten subsamples from each mash and pelleted feed for chickens for fattening 
(supplemented with 0.3 mg Se/kg from  the solid form of additive) showed CV s of 7.4 and 5.1 %, 
respectively. Tests for homogeneous distribution of selenium from the solid form of the additive in 10 
subsamples each from pelleted feed for piglets and pelleted co mplementary feed for dairy cows  
showed CVs of 4.5 and 5.3  %, respectively, at a  selenium supplementation dose of 0.3 mg Se/kg 
feed.
40  
Since the solubility in water of HMSeBA is > 491 g/L at 20 °C, confirmation of the additive‘s ability 
to be homogenously distributed in water for drinking is not required.  
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2.7.  Physico-chemical incompatibilities in feed  
No incompatibilities with feed components, carriers, other approved additives or medical products are 
expected when using HMSeBA as source of selenium in animal nutrition.  
2.8.  Conditions of use 
The conditions of use as described by applicant are as follows. The applicant proposes the use of 
HMSeBA is feed for all animal species or categories as source of selenium.  
When supplementing feed, it is proposed the solid form of additive to be added via premixtures and 
the liquid form by spraying on feedingstuffs, both up to the maximum authorised total selenium level 
0.5 mg Se/kg complete feed.  
The liquid form of  the additive is also proposed to be used in water for drinking.  The applicant 
proposes a maximum content of selenium of 0.25 mg/L in water for drinking assuming a water to feed 
intake ratio for poultry, pigs, horses and rabbits of 2. For ruminants, the applicant recommends that the 
dose of selenium added to water for drinking be adjusted according to the actual daily water intake 
and/or  an  approximate  water  consumption  (dairy  cows,  pregnant  heifers  28-114  L/day,  cattle  for 
fattening and steers 26-66 L/day, calves up to 26 weeks 9-27 L/day, small ruminants 3-15 L/day). 
Whenever the additive is used in water for drinking, the selenium content in solid feed should be taken 
into account in order to avoid and prevent the dose achieved exceeding the maximum authorised total 
selenium level in complete feed alone.  
No limitations on the age of the animals or the administration period are proposed.  
2.9.  Evaluation of the analytical methods by the  European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of the active 
substance (HMSeBA) in the feed additive and total selenium in the feed additive and animal feed. The 
Executive Summary of the EURL report can be found in the Appendix. 
3.  Safety 
The  studies  were  performed  using  either  the  pure  form  of  HMSeBA  (also  called  Selest
®)  or  the 
formulated additives (Selest
® 5 % or Selisseo 2 %). These forms are considered bioequivalent based 
on the metabolic fate of the HMSeBA and its selenium. 
3.1.  Safety for the target species  
According  to  the  Guidance  for  the  preparation  of  dossiers  for  nutritional  additives,  when  an 
application of nutritional additive is intended for all animal species/categories, the tolerance data may 
be limited to one study on one target species or laboratory animal (the most sensitive in each case) 
(EFSA, 2012b). 
3.1.1.  Tolerance studies 
The applicant provided seven non-published studies on tolerance to the target species, conducted from 
2009 to 2011. Three of those studies were regarded as preliminary trials, aiming to establish a dose 
regime to apply on the actual tolerance studies.  
The first preliminary study was performed in a total of 160 one-day-old chickens (Ross PM3) for nine 
days (40 cages x 4 birds) allotted into four groups according to dietary selenium supplementation via 
Selest
® (0.3, 0.5, 5.0 or 10 mg Se/kg diet). Analysed dietary selenium concentration was 0.27, 3.0, 5.9 
and 11 mg/kg, respectively.
41  
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The second preliminary study was performed on a total of 40 one-day-old cockerels (Ross PM3) for 
34 days. Birds were placed in three pens and fed a diet supplemented with Selest
® at a dose of 0 mg 
Se/kg  (20  birds),  10 mg  Se/kg  (10  birds)  or  5.0 mg  Se/kg  (10  birds).  Analysed  dietary  selenium 
concentration was 0.06, 0.54 and 5.20 mg/kg, respectively.
42  
The third preliminary study was performed in a total of ten weaned male castrated piglets for 43 days. 
Piglets with initial body weight (bw) of ca. 10 kg were divided into two groups of five piglets each 
and individually housed. Animals were fed diets supplemented with 0.5 or 5.0 mg Se/kg feed from 
Selest
®.
43  
In all three preliminary experiments, no significant adverse effects from the use of 10-fold selenium 
overdose from the additive (5.0 mg Se/kg) was observed either in mortality or growth performance. 
3.1.1.1.  Tolerance study in chickens for fattening (I) 
This study was combined to demonstrate both the tolerance of target species and the efficacy of the 
additive (see Section 4.1.3). A total of 720 one-day-old male chickens (Ross PM3) were allocated to 
eight groups (six replicates with 15 birds each).
44 The groups were fed  maize–soybean-based diets 
unsupplemented (selenium background: 0.05 mg/kg) or supplemented with 0.3, 0.5, 5.0 or 10.0 mg 
Se/kg from Selest
® or with 0.3, 0.5 or 5.0 mg Se/kg feed from sodium selenite for 42 days. The 
intended selenium concentration in feed was analytically confirmed. 
Body weight was measured at start, after 21 days and at termination of the trial; feed intake was 
determined  at  the  same  time  points.  At  termination,  blood  (for  glutathione  peroxidase  (GSH-Px) 
analysis)  and  tissue  samples  (liver,  muscle  for  selenium  analysis)  were  taken  from  12  birds  per 
treatment  (two  per  replicate)  and  liver  weight  was  determined.  At  day  43,  blood  samples  (for 
haematology and serum clinical biochemistry (aspartate transaminase (AST), alanine transaminase 
(ALT), γ-glutamyltransferase GGT), alkaline phosphatase (AP), creatine kinase (CK), glucose, urea, 
creatine, sodium (Na) and potassium (K)) analyses) and tissue samples (kidney, skin+fat for selenium 
analysis) from six birds per treatment (one per replicate), were taken. 
Mortality  varied  between  2.2  (10  mg  supplemented  Se/kg  from  Selest
®)  and  7.9 %  (5  mg 
supplemented Se/kg from sodium selenite). At the end of the trial, mean body weight of the control 
group was 3.27 kg. Mean body weight of the groups supplemented with 0.3 or 0.5 mg Se/kg feed from 
either sodium selenite or Selest
® was not significantly different from the control value. However, body 
weight was significantly reduced by 5 mg Se/kg from sodium selenite, and by 10 mg selenium from 
Selest
®. Feed intake followed the same pattern. For feed/gain ratio, no significant differences were 
observed between the supplemented groups and the control group. Absolute and relative liver weight 
were  similar  in  all  groups  except  a  tendency  for  an  increased  relative  liver  weight  in  the  group 
supplemented with 10 mg Se/kg from Selest
®. Haematology and clinical biochemistry (performed in 
the control group and the groups supplemented with 0.5 and 5.0 mg Se/kg from either sodium selenite 
or  Selest
®)  did  not  reveal  major  differences.  Statistical  analysis  was  not  performed;  however,  all 
values were considered to be in line with the typical data for the breed used. 
For the results of the efficacy demonstration (GSH-Px activity in plasma, selenium levels and its 
speciation in plasma, liver, muscle and skin+fat), see Section 4.1.3. 
3.1.1.2.  Tolerance study in chickens for fattening (II) 
A further study to support tolerance in chickens for fattening was performed on 206 one-day-old 
chickens  of  both  sexes  (Ross  PM3)  and  lasted  35  days.
45  Birds were divided  into four groups 
according to treatment (with 50–55 birds in each) and fed a basal diet (background selenium 0.08–0.10 
mg/kg) supplemented with 0, 0.3, 1.5 or 5.0 mg Se/kg feed from Selest
®; the intended levels were 
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analytically confirmed. Since the study was designed without replicates, zootechnical performance 
parameters could not be considered. At the end of the study, blood samples for haematological and 
biochemical  analyses  (AST,  AP,  total  bilirubin  (tBIL),  GGT,  total  cholesterol,  triglycerides, 
electrolytes, phosphorus, total protein, albumin, glucose, globulin, calcium, creatinine, AP, CK, lactate 
dehydrogenase (LDH), urea), and liver samples for histopathology examination were collected from 
eight birds per group. No treatment-related adverse effects were observed regarding mortality and final 
body weight (2.38, 2.36, 2.44 and 2.20 kg). Necropsy, liver histology, haematology and biochemistry 
results did not reveal any treatment-related differences between groups. 
3.1.1.3.  Tolerance study in turkeys  
A study carried out in 180 one-day-old turkeys (both sexes of BUT 9) fed a basal diet (background 
selenium 0.05 mg/kg) supplemented according to treatments with 0, 0.3 or 5.0 mg Se/kg feed from 
Selest
® for 42 days.
46 Analyses showed a selenium content in the respective diets ranging from 0.1 to 
0.34 mg Se/kg, from 0.49 to 0.56 and from 4.44 to 4.80 mg Se/kg diet, respectively. There were six 
replicates per treatment (three per gender), which ten birds in each pen as replicate. At the end of the 
trial, blood samples for biochemistry (AST,  AP, GGT, sodium, potassium, phosphorus, total protein, 
albumin, glucose, globulin, calcium, CK, LDH, urea and uric acid) and haematology (red blood cells 
(RBC), white blood cells (WBC), haematocrit (HCT), haemoglobin (Hb), mean corpuscular volume 
(MCV) and leucogram), as well as liver and kidney samples for histopathology examination , were 
collected from one bird per replicate. Overall, the growth performance of birds fed diets supplemented 
with selenium from Selest
® did not differ from that of the control unsupplemented group. However, 
the body weight of the birds supplemented with 0.3 mg Se/kg feed was slightly lower, but in the group 
supplemented with 5.0 mg Se/kg it was similar to that of control group. Feed to weight gain ratio 
(1.85, 1.99 and 1.78 kg/kg in the control group, and the groups supplemented with 0.3 and 5.0 mg 
Se/kg diet, respectively) showed significant differences only between the high-selenium group and 
low-selenium  group,  but  no  differences  were  observed  between  the  high-selenium  group  and  the 
unsupplemented  birds.  These  findings  are  not  considered  to  be  treatment-related.  The  serum 
biochemistry and haematology parameters were within the expected reference range in all groups and 
thus there was no indication of any treatment related effect. Gross pathology and histopathological 
examination did not reveal any adverse effects of the highest dose of selenium from Selest
®. 
3.1.1.4.  Tolerance study in piglets  
A 42-day study was performed in 40 weaned piglets (Dutch Landrace, Finnish Landrace and Piétrain) 
with initial body weight of 8.0–12.5 kg. Animals were divided into four groups (five males and five 
females  per  group).
47  Since the study was designed without replicates, zootechnical performance 
parameters could not be considered.  Piglets were fed diets supplemented with 0, 0.3, 1.5  or 5.0 mg 
Se/kg feed from Selest
®. The selenium supplementation was analytically confirmed. At the end of the 
study blood samples for haematology (RBC, WBC, HCT, Hb, and leucogram) and biochemistry (AST, 
ALT, GGT, AP, LDH, glutamate dehydrogenase, tBIL, total cholesterol, triglycerides, phospholipids, 
electrolytes, phosphorus, total protein, albumin, glucose, globulin, calcium, creatinine, urea), and liver 
samples  for  histopathology  were  collected  from  eight  animals  per  treatment;  these  animals  were 
subsequently subjected to gross pathology examination. No treatment-related liver gross pathology 
and  histopathology  findings  were  observed  at  the  end  of  study.  Haematological  and  biochemical 
parameters were not affected by the treatments; only creatine kinase activity was increased in piglets 
fed a diet with the highest level of selenium supplementation (5.0 mg/kg). No differences in final body 
weight within a gender were observed between groups. No mortality occurred.  
3.1.2.  Conclusions on the safety for target species  
Supplementation of selenium  from HMSeBA to feed for chickens for fattening  up to 10-fold the 
maximum authorised level did not show adverse effects whereas the highest equivalent dose of sodium 
selenite led to reduced body weight of chickens for fattening. The absence of significant adverse 
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effects  at  10-fold  overdose  of  selenium  from  HMSeBA  was  also  confirmed  in  further  studies  in 
chickens  for  fattening  and  other  trials  in  piglets  and  turkeys.  Considering  the  zootechnical 
performance, haematological and biochemistal parameters as endpoints, a safety margin of ten was 
identified. The contribution of the metabolite hydroxy-analogue of methionine from HMSeBA to the 
animal methionine pool would be negligible considering the limit set by the EU on maximum total 
selenium level in feed. The additive HMSeBA is considered to be a safe source of selenium for all 
species/categories when used up to total maximum authorised selenium content in complete feed. 
3.2.  Safety for the consumer  
3.2.1.  Metabolic and tissue/product deposition studies  
HMSeBA is the DL-form of 2-hydroxy-4-methylselenobutyric acid and is similar to 2-hydroxy-4-
methylthiobutanoic acid, well known in animal nutrition as methionine hydroxy-analogue, which is 
readily converted to methionine in vivo. In HMSeBA, the sulphur atom is replaced by a selenium 
atom. HMSeBA therefore undergoes the same metabolism as the methionine hydroxy-analogue but 
resulting in selenomethionine (Se-Met), the metabolism of which provides dihydrogen selenide (H2Se) 
for the biosynthesis of specific selenoproteins. It is well established that some proportion of Se-Met 
escapes its metabolism to H2Se and is non-specifically incorporated into the general body proteins. 
This metabolic fate of Se-Met is based on the fact that tRNA(Met) in plants, bacteria, birds and 
mammals  does  not  discriminate  between  the  common  amino  acid  methionine  (Met)  and  Se-Met. 
Therefore  both  Met  and  Se-Met  may  substitute  for  each  other  during  incorporation  into  general 
proteins (Schrauzer, 2000). Consequently, edible tissues and animal products—particularly meat, eggs 
and  milk—from  animals  fed  diets  supplemented  with  selenium  sources  based  on  Se-Met  as  the 
predominant selenocompound, contain significantly more selenium than those from animals given 
inorganic sources of selenium (Mahan and Parrett, 1996; Knowles et al., 1999; Ševčíková et al., 2006; 
Skřivan et al., 2006; Skřivan et al., 2010). 
3.2.1.1.  In vivo transformation of HMSeBA 
In  a  preliminary  study,  six  rats  were  dosed  with  1  mg  HMSeBA/kg  bw  and  sampled  at  four 
consecutive time points.
48 HMSeBA, Se-Met, selenocysteine (Se-Cys) and other seleno-metabolites 
were analysed by HPLC-ICP-MS (HPLC-inductively coupled plasma mass spectrometry)  and total 
selenium by ICP-MS. Within three hours after gavage, HMSeBA concentrations in plasma  fell below 
the LOD (20 µg HMSeBA/L), whereas Se-Met and also Se-Cys were still detected after six hours. In 
addition, the content of total selenium in plasma and in muscle tissue increased rapidly (within one 
hour after gavage) and stayed fairly constant in the  six-hour time period. Se-Met was detected in 
muscle tissue, whereas HMSeBA was not. It was concluded that HMSeBA is rapidly transformed into 
Se-Met and other metabolites. 
The effect of selenium source and level on tissue selenium deposition was studied  in chickens for 
fattening.
49 Six groups with six replicates of 17 chickens each were fed different selenium sources and 
levels from 0 to 21 days of age. Five groups were given a basal diet containing selenium either from 
sodium selenite (0.1 or 0.3 mg Se/kg feed) or from HMSeBA (0.1, 0.2 or 0.3 mg Se/kg feed), and the 
control group  was fed  the basal diet  not  supplemented  with  selenium. Growth performance w as 
measured throughout the experimental period and muscle samples (breast muscle) were collected at 
the end of the experimental period.  The comparison of the different selenium sources indicated that 
muscle selenium concentrations were higher following supplementation with HMSeBA than with  
sodium selenite. Theoretical selenium levels  of 0.1 and 0.3 mg/kg feed  resulted in muscle selenium 
concentrations of 1.63 an d 3.88 times higher  in the  HMSeBA-treated groups  than in the sodium 
selenite-treated groups. HMSeBA was measured in six muscle samples from chickens fed HMSeBA at 
0.3 mg Se/kg feed; results indicated a muscle HMSeBA concentration below the detection level (0.01 
mg selenium from HMSeBA/kg). Moreover, the same samples, together with six other samples of the 
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control group, were analysed for selenium speciation (Se-Met and Se-Cys); results suggested that 
muscle selenium was mainly present in the form of Se-Met and Se-Cys. The results of this study 
indicated that (i) HMSeBA is not retained in muscle tissue and (ii) higher muscle selenium would 
result from the use of HMSeBA compared with the inorganic source, sodium selenite. 
3.2.1.2.  Tissue deposition study in chickens for fattening 
Groups of 12 one-day-old male and 12 one-day-old female chickens for fattening (Ross PM3) received 
soybean–maize-type diets supplemented with 0.3 or 0.5 mg Se/kg from HMSeBA or 0.5 mg selenium 
from sodium selenite for 35 days.
50 The supplementation levels in feed were analytically confirmed. 
At day 36, blood samples were taken from six birds per group; thereafter the birds were slaughtered 
for tissue collection. No significant differences in body weight and feed intake were observed at the 
end of the study. The results of plasma and tissue analyses are summarised in Table 2. 
Table 2:   Selenium  levels  in  plasma  and  tissues  of  chickens  for  fattening  after  feeding  diets 
supplemented with selenium either from HMSeBA or from sodium selenite for 35 days.  
Group 
Selenium levels (mg/kg) 
Plasma  Liver  Kidney  Muscle  Skin+Fat 
Sodium selenite (0.5 mg Se/kg)  0.23  0.64  0.77  0.14  0.15 
HMSeBA (0.3 mg Se/kg)  0.27  0.84  0.97  0.45  0.21 
HMSeBA (0.5 mg Se/kg)  0.29  1.07  1.16  0.62  0.26 
The tissue and plasma residue analysis indicated that selenium was present in higher quantities in the 
HMSeBA-supplemented group than in the sodium selenite-supplemented group (4.4 times the level in 
muscle  at  equal  selenium  supplementation  level).  GSH-Px  activity  in  plasma  was  systematically 
affected by the treatment (range of individual values: 63–102 nmol nicotinamide adenine dinucleotide 
phosphate (NADPH)/min/mL). HMSeBA could not be detected in tissues. 
3.2.1.3.  Tissue deposition study in turkeys for fattening 
Two groups of 12 one-day-old BUT 9 turkeys (six males and six females in each group; each group 
housed in cages) were fed soybean–maize-type diets supplemented with 0.5 mg Se/kg either from 
sodium selenite or from HMSeBA for 84 days.
51 No control unsupplemented group was included.  
Since the study  was designed without replicates, zootechnical performance parameters could not be 
considered. The selenium supplementation was analytically confirmed. At the end of the study, the 
birds were sacrificed, and blood and tissue samples from liver, kidney, muscle and skin+fat were taken 
and analysed for selenium content.  
No differences in final body weight within a gender were observed between groups.  The results of 
selenium analysis in plasma and tissue samples are summarised in Table 3. 
 
 
Table 3:   Selenium levels in plasma and tissues of turkeys after feeding diets supplemented with 
selenium either from HMSeBA or from sodium selenite for 84 days 
Group 
Selenium levels (mg/kg) 
Plasma  Liver  Kidney  Muscle  Skin+Fat 
Sodium selenite (0.5 mg Se/kg)  0.12  0.71  0.84  0.25  0.16 
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HMSeBA (0.5 mg Se/kg)  0.19  1.30  1.07  0.60  0.31 
The tissue and plasma selenium analysis indicated that selenium was present in higher quantities in the 
HMSeBA-supplemented group than in the group given sodium selenite (2.4 times the level in muscle). 
3.2.1.4.  Egg deposition study in laying hens 
Three groups of 20 Lohmann Brown laying hens (24 weeks of age; bw 1723 g) were fed wheat–
soybean-type diets supplemented with 0.3 or 0.5 mg Se/kg from HMSeBA or 0.5 mg selenium from 
sodium selenite for 42 weeks.
52 The average analysed selenium concentration in feed (mean of three 
samples) was 0.40 and 0.57 mg/kg , respectively, in the groups supplemented with 0.3 and 0.5 mg 
selenium from HMSeBA and 0.41 mg in the group receiving 0.5 mg/kg supplemental selenium from 
sodium selenite. All eggs were collected daily; for  selenium  analysis,  ten  eggs per group were 
collected prior to  the  start,  at 56, 112 days and 168 days (cessation) after  the  start. No relevant 
differences in feed intake, laying rate and egg weight were observed during the trial. The results of the 
selenium analyses in eggs are shown in Table 4. 
Table 4:   Selenium  concentration  in  egg  homogenates  after  feeding  diets  supplemented  with 
selenium either from sodium selenite or from HMSeBA for 168 days to laying hens.  
Group 
Selenium levels in egg homogenates (mg/kg) 
At start  56 days  112 days  168 days 
Sodium selenite (0.5 mg Se/kg)  0.28  0.26  0.26  0.23 
HMSeBA (0.3 mg Se/kg)  0.29  0.37  0.38  0.36 
HMSeBA (0.5 mg Se/kg)  0.26  0.49  0.53  0.48 
The selenium content in eggs homogenates appeared to plateau after 56 days of feeding, after which 
time no further increases were observed. Average values for the three sampling dates were 0.25 mg 
Se/kg egg homogenate in the sodium selenite group, 0.37 mg Se/kg (1.5 times the level in the sodium 
selenite group) in the group supplemented with 0.3 mg Se/kg from HMSeBA and 0.50 mg Se/kg (2 
times  the  level  in  the  sodium  selenite  group)  in  the  group  supplemented  with  0.5  mg/kg  from 
HMSeBA. No HMSeBA could be detected in egg homogenates (LOQ 100 ng HMSeBA/g). 
3.2.1.5.  Tissue deposition study in pigs for fattening 
Three  groups  of  six  pigs  for  fattening  (both  genders;  commercial  pigs:  Dutch  Landrace,  Finnish 
Landrace and Piétrain; body weight at start between 36.3 and 53.0 kg) were kept in one pen each and 
received maize–soybean–barley-type diets supplemented with 0.3 or 0.5 mg Se/kg from HMSeBA or 
0.5 mg Se/kg from sodium selenite for 84 days.
53 Analysis showed the selenium content of the diets to 
be 0.47 mg, 0.65 mg and 0.64 mg total Se/kg feed, respectively. Two pigs (receiving 0.5 mg Se/kg 
from HMSeBA) died during the trial (one from malignant lymphoma, one from gastric ulcer) . After 
cessation of the treatment, the animals were sacrificed, blood and tissue (liver, kidney, muscle ( M. 
semitendinosus and M. semimembranosus) and skin+fat) samples were collected. Total selenium and 
HMSeBA and Se-Met (qualitatively) were analysed in all samples, and GSH-Px activity in muscle. 
Differences in body weight gain were not observed (mean: 932 g/day). The average data for total 
selenium in plasma and tissues, as well for GSH-Px activity in muscle tissue, are summarised in Table 
5. 
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Table 5:   Selenium levels in plasma and tissues and GSH-Px activity in muscle of pigs for fattening 
after feeding diets supplemented with selenium either from HMSeBA or from sodium 
selenite for 84 days.  
Group  GSH-Px activity*  Selenium levels (mg/kg) 
Muscle  Plasma  Liver  Kidney  Muscle  Skin+Fat 
Sodium  selenite  (0.5  mg 
Se/kg) 
34.6  0.18  0.62  1.53  0.17  0.06 
HMSeBA (0.3 mg Se/kg)  44.2  0.22  0.80  1.50  0.38  0.09 
HMSeBA (0.5 mg Se/kg)  52.3  0.24  1.02  1.95  0.55  0.13 
* nmol NADPH/min/mL 
HMSeBA could not be quantified (LOQ= 100 ng/g) in any sample. Se-Met could not be detected in 
any plasma or muscle tissue samples. In the group supplemented with sodium selenite, the presence of 
Se-Met was shown in two out of six skin+fat samples, but not in any other samples (kidney and liver). 
In the group supplemented with the same selenium level from HMSeBA, Se-Met could be detected in 
all four liver and kidney samples and in three of four skin+fat samples. 
At equivalent dietary selenium concentrations, muscle selenium was about 3.2 times higher in the 
HMSeBA-supplemented group than in the sodium selenite-supplemented group. 
3.2.1.6.  Milk deposition study in dairy cows 
Twenty-four Holstein cows (209 days in milk, on average, at the beginning of the experiment), were 
fed three different diets for 53 days, which varied only in sources of selenium.
54 All cows were fed 
maize silage ad libitum, and received an additional silage and concentrate (adjusted to individual milk 
yield) as a total mixed ration. The feed of the negative control group was not supplemented with 
selenium. Each cow in the other two groups received 2.4 mg Se/day from sodium selenite or HMSeBA 
via complementary feed. The selenium supplementation was analytically confirmed. There was no 
significant influence of the different selenium sources on milk production (average: 35.2 kg/day) or 
milk quality (average 3.16 % protein and 3.64 % fat). Milk selenium concentration, measured on the 
last three days of the experiment, in the unsupplemented control group and the groups given selenium 
either  from  sodium  selenite  or  from  HMSeBA  was  0.009,  0.014  and  0.017 mg/kg  fresh  product, 
respectively.  This  result  suggests  that  the  potency  of  selenium  from  HMSeBA  in  increasing  the 
selenium level in milk is only 1.2 times higher than that of selenium from sodium selenite, being lower 
than the potency factor identified for poultry and pig muscle and eggs. However, only a relative low 
dose of selenium from HMSeBA (2.4 mg/head/day) in dairy cows, with a mean dry matter (DM) 
intake per day of 22.9 kg—thus corresponding to and intake of only 0.1 mg Se/kg DM—was tested. 
The FEEDAP Panel notes that organic selenium  such as selenised yeast, in which Se-Met is the 
predominant  selenium  form  (selenised  yeasts  contains  ≥90%  selenium  in  the  form  of  Se-Met 
(Schrauzer,  2006)),  when used  as  a selenium  source  in  dairy  cows,  shows  3.6  higher  potency  to 
increase milk selenium content compared to sodium selenite (meta-analysis of 33 studies; Ceballos et 
al., 2009).  
Therefore, in the absence of a dose–response study with HMSeBA in dairy cows and considering (i) 
Se-Met  being  a  resulting  metabolite  of  HMSeBA  and  (ii)  the  established  knowledge  on  Se-Met 
metabolic  fate  in  food-producing  animals,  the  FEEDAP  Panel  does  not  expect  that  the  use  of 
HMSeBA as a source of selenium in nutrition of dairy cows would result in a different pattern of milk 
selenium deposition than that resulting from the use of selenised yeasts. 
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3.2.1.7.  Conclusions on metabolic and tissue/product deposition studies  
HMSeBA is converted to selenomethionine; consequently, no residues of the compound itself occur in 
animal tissues and products. Based on data provided and the metabolic fate of HMSeBA, the FFEDAP 
Panel concludes that the use of HMSeBA as a source of selenium in feed would lead to significantly 
higher selenium levels in animal tissues/animal products than the standard inorganic selenium source 
sodium selenite and thus to levels comparable to those resulting from the use of selenised yeasts. 
3.2.2.  Toxicological studies 
3.2.2.1.  Acute toxicity 
Three  acute  oral  toxicity  trials  with  HMSeBA  were  performed  in  rats
55  and mice,
56  according to 
OECD guideline 423 ("Acute Toxic Class Method"). 
In rats the LD50 ranged between 10 and 25 mg HMSeBA/kg bw, and in mice between 25 and 50 mg 
HMSeBA/kg bw, indicating that HMSeBA is hazardous by the oral route. A comparative study in 
rats
57 indicated that the acute oral toxicity of HMSeBA is comparable to that of L-SeMet and is higher 
than that of sodium selenite (LD50 higher than the top dose level tested, 43.6 mg/kg bw).  
3.2.2.2.  Genotoxicity studies including mutagenicity 
The  mutagenic  potential  of  HMSeBA  was  tested  in  Salmonella  Typhimurium  strains  TA1535, 
TA1537, TA98, TA100 and TA102 in the presence or absence of metabolic activation (S9 fraction 
from  liver  of  rats  pre-treated  with  Aroclor  1254), in  compliance  with  OECD  guideline  471  (rev. 
1997).
58 The test item was tested up to cytotoxic levels. No evidence of mutagenicity was seen in any 
bacterial strain in two independent experiments, while the concurrent positive controls demonstrated 
the sensitivity of the assay and the metabolising activity of the liver preparations.  
HMSeBA was tested for the ability to induce gene  mutations at the thymidine kinase (TK) lo cus in 
L5178Y mouse lymphoma cells in the presence and in the absence of metabolic activation (S9 fraction 
from liver of rats pre -treated with Aroclor 1254), in compliance with OECD guideline 476 (rev. 
1997).
59 The test item was tested up to cytotoxic level s. Under the experimental conditions of this 
study, HMSeBA showed mutagenic activity in the mouse lymphoma assay, in the presence of S9 mix, 
while in the absence of S9 mix the result remained equivocal. 
An  in  vitro  chromosome  aberrations  test  was  conducted  in  cultured  human  lymphocytes  with 
HMSeBA, in two independent experiments (OECD guideline 473, rev. 1997).
60 The cells, isolated 
from pooled blood taken from healthy male donors, were exposed to the test article both in the 
presence and in the absence of S9-mix derived from the liver of rats pre-treated with Aroclor 1254. In 
the first experiment, lymphocyte cultures were exposed to the test or control item (with or without S9 
mix) for  three  hours  and  then rinsed. Cells were harvested 20 hours after the begi nning of  the 
treatment, corresponding to approximately 1.5 normal cell cycles. The second experiment was 
performed without S9 mix, cells being exposed continuously to the test or control items until harvest, 
or with S9 mix, cells being exposed to the test or control items for three hours and then rinsed. Cells 
were harvested 20 hours and 44 hours after the beginning of  the  treatment, corresponding to 
approximately 1.5 normal cell cycles and 24 hours later, respectively. The test item was tested  at 
levels up to 2500 μg/mL without S9 mix and at levels up to 1500 μg/mL with S9 mix, as higher levels 
produced excessive cytotoxicity. In the experiments without S9 no effect was seen after three hours, 
while  a  statistically  significant  increase  in  the  frequency  of  cells  with  structural  chromosomal 
aberrations was observed after the 20-hour treatment. The first experiment with S9 mix was negative. 
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In contrast, a dose-related effect was observed in the second experiment for a 20-hour harvest; after 
44-hour treatments a slight, non significant effect, was observed both with and without metabolic 
activation.  
The potential of HMSeBA to induce structural or numerical damage in rat bone marrow cells in vivo 
was tested by the micronucleus test (OECD Guideline 474, 1997).
61 Three groups of five male and 
five female Sprague–Dawley rats received two oral treatments of HMSeBA at dose levels of 3.75, 7.5 
or 15 mg/kg bw per day (males) and 2.5, 5 or 10 mg/kg bw per day (females), at 24-hour intervals. 
The top dose levels were selected on the basis of the systemic toxicity observed in the preliminary test. 
The animals were sacrificed 24 hours after the last treatment and bone marrow smears were then 
prepared. For each animal, the number of the micronucleated polychromatic erythrocytes (MPE) was 
counted in 2000 polychromatic erythrocytes. No statistically significant increase in the frequencies of 
MPE was found in the treated animals, when compared with the untreated control, while the positive 
control  (cyclophosphamide)  produced  the  expected  response.  A  significant  reduction  in  the 
polychromatic/ normochromatic erythrocytes ratios of treated animals indicated that the bone marrow 
cells were effectively exposed to the test item. 
3.2.2.3.  Subchronic repeated dose oral toxicity studies  
A preliminary dietary 28-day study was performed in Sprague–Dawley rats administered HMSeBA as 
a dose-finding trial for the ensuing subchronic, 90-day study.
62 Dietary concentrations leading to dose 
levels  ≥ 4 mg/kg  bw  per  day  were  not  tolerated,  with  animals  showing  poor  condition  and  liver 
damage;  exposure  to  0.9 mg/kg  bw  per  day  was  tolerated,  with  animals  showing  prolonged 
prothrombin time and lower plasma triglycerides (females), as well as hepatocellular hypertrophy 
(both sexes). Exposure to 0.25 mg/kg bw was the no observed adverse effect level (NOAEL) of the 
dose-finding study. 
In the 90-day study (performed according to OECD guideline 408), four groups of Sprague–Dawley 
rats (ten of each sex per group) were exposed through the diet to feed concentrations with mean 
exposure levels of 0 (unexposed), 0.025, 0.125 and 0.625 mg HMSeBA/kg bw per day. The initial 
concentration was adjusted weekly according to the mean body weight gains and feed consumption of 
test  animals.  Blood  chemistry,  biochemistry  and  haematological  parameters,  gross  pathology  and 
histopathology  were  assessed;  full  pathology  examinations  were  performed  in  the  high-dose  and 
control animal groups, whereas liver was also examined in mid-dose animals. Slight toxicity was 
observed at the top dose level only, and mainly in females, namely: higher plasma cholesterol and 
triglyceride concentrations (females), increased relative liver weight (both sexes) and, centrilobular 
hepatocellular hypertrophy (females). Dietary exposure to 0.125 mg/kg bw per day was the NOAEL. 
3.2.2.4.  Conclusions on toxicological studies 
At the inclusion levels proposed in feed, HMSeBA is not expected to cause acute toxicity.  
The  compound  resulted  negative  in  the  bacterial reverse  mutation  assay,  but  displayed  genotoxic 
activity  in  two  in  vitro  assays  in  mammalian  cells:  chromosomal  aberrations  in  cultured  human 
lymphocytes with and without metabolic activation, and gene mutations in mouse lymphoma cells 
with metabolic activation (equivocal results were observed without S9 mix). This genotoxic potential 
was not confirmed in vivo; the in vivo micronucleus assay was clearly negative under experimental 
conditions in which evident toxicity was reported in bone marrow, showing that the target cells were 
sufficiently exposed to the test item. Therefore, on the basis of the experimental results, the test item 
should not be considered genotoxic in vivo. At the trace levels normally found in biological systems, 
selenium is a pro-antioxidant and a potential antimutagenic agent, whereas at higher concentrations it 
may  work  as  pro-oxidant  and  cause  DNA  damage.  This  may  explain  the  positive  findings  for 
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genotoxicity in some in vitro tests of the HMSeBA and other forms of selenium in which high levels 
of local exposure are reached. 
A  90-day  study  in  rats  indicated  that  dietary  exposure  to  HMSeBA  elicits  liver  effects,  more 
pronounced in female rats, with Lowest Observed Adverse Effect Level (LOAEL) and NOAEL of 
0.625  and  0.125  mg/kg  bw  per  day,  respectively.
63  No toxic effects unexpected in a selenium 
compound were observed. When compared to the selenium  upper level on body weight basis (0.3 
mg/70 kg= 0.004 mg/kg bw), the NOAEL provides an approximate 30-fold safety margin. 
3.2.3.  Consumer exposure assessment 
The data on metabolism and tissue deposition after application of HMSeBA clearly demonstrate that 
(i) HMSeBA is a source of available selenium, (ii) no residues of the compound itself occur in animal 
tissues and (iii) HMSeBA is converted to Se-Met. 
HMSeBA at 0.5 mg Se/kg feed increased muscle selenium compared with sodium selenite in chickens 
by a factor of 4.4, in turkeys by 2.4 and in pigs by 3.2. In eggs, this factor for HMSeBA in relation to 
sodium selenite was 2. Owing to the limitations of the milk study in dairy cows, an appropriate factor 
for milk selenium deposition from HMSeBA could not be set. However, the FEEDAP Panel concludes 
that milk selenium deposition from the use of HMSeBA as feed additive would not be different to that 
from selenised yeast, thus leading to significantly higher selenium milk levels than those derived from 
use of an inorganic selenium source, and comparable to those resulting from the use of selenised 
yeasts, as is the case for the other animal tissue/products tested. 
When assessing the consumer safety of selenised yeast-based additives (EFSA, 2011a, b, 2012a), the 
FEEDAP Panel noted that there  are likely no principal differences in the metabolic behaviour of 
selenium from different selenised yeasts (containing Se-Met as the predominant selenium form) when 
fed to animals. Selenium deposition resulting from the use of these selenised yeasts as feed additives 
was  considered  to  result  in  similar  selenium  tissue  deposition  and  product  concentrations,  and 
significantly  higher  than  those  resulting  from  the  use  of  the  inorganic  selenium  source,  sodium 
selenite. The FEEDAP Panel considers that the HMSeBA factors for selenium deposition in animal 
edible tissues/products are of the same magnitude as those derived for selenised yeasts. 
The above conclusion on the similar behaviour of Se-Met from different selenised yeasts in terms of 
selenium tissue and product deposition, can, therefore, be extended to HMSeBA. A detailed estimate 
of consumer exposure to food from HMSeBA-supplemented animals is therefore not necessary. 
3.2.4.  Conclusions on the safety for consumers  
Based on a toxicology testing package (acute toxicity, genotoxicity in vitro and in vivo and repeated 
dose toxicity) HMSeBA does not elicit any adverse effects not expected in a selenium compound. 
HMSeBA is converted to Se-Met; consequently, no residues of the compound itself occur in animal 
tissues and products. Regarding consumer exposure to selenium from the use of HMSeBA in animal 
nutrition,  the  FEEDAP  Panel  extends  its  former  conclusion  on  the  maximum  selenium 
supplementation of feed from selenised yeasts and states that a maximum supplementation level of 0.2 
mg Se/kg feed from HMSeBA would be unlikely to result in a health risk tor consumers, including 
children of one to three years. 
3.3.  Safety for the user 
The dusting potential, the selenium content of the dust (approximately 1 %) and the respirable fraction 
of about 25 % indicate that users may be exposed by inhalation to HMSeBA when using the solid form 
of the additive. 
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In an acute inhalation study on rats performed according to the OECD guideline 403, mortality was 0, 
40 and 90 % at Selisseo concentrations of 1.1, 2.5 and 5.5 mg/L air, respectively.
64 Dose-related non-
lethal effects were observed in all three treated groups, including ruffled fur, tachypnoea and transient 
weight loss. The results indicate that Selisseo is hazardous by inhalation. 
In a series of good lab oratory practice (GLP) studies,
65 the additive resulted only in a slight skin 
irritation and should not be classified as skin irritant. It was found to be an eye irritant in rabbits. It did 
not show any sensitisation potential in a mouse local lymph node assay. 
3.3.1.  Conclusions on the safety for the users 
The additive should be regarded as an eye irritant, but should not be classified as skin irritant or skin 
sensitiser. Inhalation exposure poses a hazard to users; the FEEDAP Panel concludes, therefore, that 
the formulation and conditions of use of the solid form of the additive should minimise user exposure 
by inhalation. 
3.4.  Safety for the environment 
The FEEDAP Panel considers that the use of HMSeBA in feed does not pose an additional risk to the 
environment, compared with other sources of selenium for which it will substitute, as long as the 
maximum authorised content in feedingstuffs is not exceeded. 
4.  Efficacy 
Evidence of in vivo bioavailability can be taken to support efficacy for compounds of essential trace 
elements. One trial in a single animal species, including laboratory animals, is considered sufficient. 
As already established in previous opinions of the FEEDAP Panel (EFSA 2006a, b, 2009a, 2011a, 
2012a),  the  bioavailability  of  a  source  of  selenium  as  nutritional  additive  is  considered  to  be 
demonstrated if one of the specific endpoints (glutathione peroxidase (GSH-Px) activity in plasma or 
whole blood, selenium concentration in plasma/serum or whole blood, selenium content in liver) is 
significantly influenced by the test item. 
Tissue deposition of selenium from selenised yeast, in which the predominant selonocompound is Se-
Met, was considered to reflect directly only the unspecific incorporation of Se-Met into general body 
proteins (EFSA, 2006a). After being absorbed, HMSeBA is metabolised to Se-Met; consequently, the 
metabolic fate of its selenium is, in principle, identical to that of Se-Met from a selenised yeast. Since 
the  utilisation  of  selenium  from  Se-Met  in  body  proteins  for  specific  selenium  functions  is  well 
known, selenium deposition in tissues is taken as indirect proof of selenium bioavailability from each 
additive with a mode of action based on enriching the Se-Met body pool.  
Data  from  seven  studies  (four  in  chickens  for  fattening,  two  in  laying  hens  and  one  in  pigs  for 
fattening) have been provided to demonstrate the efficacy of HMSeBA as a source of selenium.  
4.1.  Chickens for fattening 
4.1.1.  Study 1 
A short-term efficacy/selenium digestibility study was conducted in 96 one-day-old male chickens for 
fattening (Ross PM3), housed in cages for 24 days and allocated to four dietary treatments (each with 
24 replicates of one chicken).
66 A maize–soybean meal-containing diet was supplemented with 0.3 mg 
Se/kg  feed  from  either  sodium  selenite,  HMSeBA,  HMSeBA  on  starch  or  HMSeBA  on  silica 
(selenium contents confirmed by analysis). Diets were fed ad libitum in crumble form (days 0–13) or 
as pellets (days 14–24). To analyse faecal digestibility of selenium, the excreta were collected from 12 
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chickens per treatment during the last three days of trial. At the end of study, breast muscle samples 
from 12 chickens per treatment were collected. 
Owing to the short duration of the study, zootechnical performance data could not be considered. The 
apparent  faecal  selenium  digestibility  was  increased  from  about  23 %  (sodium  selenite)  to  50 % 
(HMSeBA) while no differences were found between various HMSeBA sources. In comparison with 
the  sodium  selenite  treatment,  selenium  in  muscle  was  significantly  increased  in  the  HMSeBA 
treatments from about 0.3 to 1.2 mg Se/kg DM.  
4.1.2.  Study 2 
A long-term efficacy study was conducted with 600 one-day-old male chickens for fattening (Ross 
PM3),  housed  in  floor  pens  for  42  days  and  allocated  to  four  dietary  treatments  (six 
replicates/treatment, 25 chickens per pen/replicate).
67 A basal maize–soybean meal diet (background 
selenium content 0.07 mg/kg) was supplemented with 0 or 0.3 mg Se/kg feed from selenite or with 0.1 
or 0.3 mg Se/kg feed from HMSeBA. The selenium supplementation was confirmed by feed analysis. 
Diets were fed ad libitum as pellets (as crumbles days 0–5) in two phases (starter: days 0–21; finisher: 
days 21–42). Animal performance was recorded. At day 42, samples of blood, breast muscle and liver 
from  two  birds  per  pen  were  collected  for  analysis  of  selenium  level  and  speciation  of 
selenocompounds. The quality of meat (breast samples from three birds per pen) stored at 4°C for up 
to eight days was assessed by measurements of pH, drip loss, thiobarbituric acid-reactive substances 
(TBARS) and colour.  
Mortality ranged between 2.0 and 5.3 %, and was not related to treatments. The statistical analysis did 
not show any effect on final body weight (mean 3347 g), feed intake (mean 6575 g) or feed/gain ratio 
(mean  1.97).  All  groups  treated  with  additional  selenium  showed  a  significantly  higher  selenium 
concentration in plasma and tissues (P< 0.05) than the unsupplemented control. The significantly 
highest selenium concentrations in plasma and tissue samples were found in birds treated with a higher 
supplementation  level  of  selenium  from  HMSeBA.  The  predominant  selenocompound  found  in 
plasma and liver was Se-Cys whilst in muscle Se-Met seemed to be the main selenocompound. No 
significant differences between the treatments were observed on ultimate pH, drip loss, TBARS and 
meat colour.  
4.1.3.  Study 3 
Data on efficacy are derived from a report on a combined tolerance–efficacy study carried out in 
chickens for fattening (for description see Section 3.1.1.1).
68 In this study the comparison of birds fed 
an unsupplemented diet and groups on diets supplemented with 0.3 mg Se/kg feed either from sodium 
selenite or  HMSeBA  (Selest
®),  showed  a  significant  increase  in  plasma  GSH-Px  activity  in  both 
supplemented groups compared with the control group, but without significant differences between the 
sources of selenium. Liver and muscle selenium increased with rising dietary selenium from both 
sources,  as  did  kidney  and  skin+fat  selenium.  Supplementation  with  HMSeBA  resulted  in 
considerably  and  significantly  higher  tissue  selenium  concentrations  than  supplementation  with 
sodium  selenite.  Selenium  speciation  (for  treatment  0.5  mg  supplemental  Se/kg  from  HMSeBA) 
indicated  that  Se-Met  and  Se-Cys  were  present  in similar concentrations  in muscle  and  skin+fat, 
whereas significantly higher Se-Cys concentrations were found in liver and kidney. The selenium level 
from  both  Se-Met  and  Se-Cys  was  not  statistically  different  from  total  selenium,  indicating  that 
HMSeBA was effectively converted to Se-Met (and further to Se-Cys). 
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4.2.  Laying hens 
4.2.1.  Study 1 
A study was conducted in 160 ISA Brown laying hens (initial age 40 weeks), housed in pens for 56 
days and allocated to four dietary treatments (eight replicates of five hens).
69 The unsupplemented 
maize and soybean meal-based diet with background selenium content of 0.07 mg/kg (control) was 
enriched with 0.2 mg Se/kg from sodium selenite or with 0.1 or 0.2 mg Se/kg feed from  HMSeBA. 
Selenium supplementation was confirmed by analysis. Diets were fed  ad libitum. On the last three 
days, three eggs per pen were collected for analysis of selenium content. The eggs from hens fed 
supplemented diets showed significantly higher selenium content than those from control birds on 
unsupplemented  diet  (P<  0.05).  In  hens  supplemented  with  the  highest  HMSeBA  dose,  the  egg 
selenium content was significantly the highest (1.1 mg /kg DM) whereas eggs from unsupplemented 
control group showed only 0.3 mg Se/kg DM. 
4.2.2.  Study 2 
A study was conducted in 60 ISA Brown laying hens (initial age 30 weeks), individually housed in 
pens  and  allocated  to  five  dietary  treatments  (12  replicates  with  one  hen  in  each).
70  A control 
unsupplemented diet based on  maize and soybean meal (background selenium content: 0.07 mg/kg) 
was supplemented with 0.1 or 0.3 mg Se/kg feed either from sodium seleni te or HMSeBA. Selenium 
supplementation was confirmed by analysis. Diets were fed  ad libitum. After a 14-day adaptation 
period, the collection of eggs started at the beginning of experimental phase and continued at two-
week intervals for 56 days. Owing to the short duration of the trial, laying performance (97 % laying 
rate on average) is not further considered. For each collection day, the significantly lowest selenium 
concentration was observed in eggs from the control unsupplemented group and the highest in eggs 
from hens supplemented with 0.3 mg Se/kg feed from HMSeBA. In general, the response in egg 
selenium was dose dependent. However, at the supplementation level of 0.3 mg Se/kg feed, HMSeBA 
resulted in significantly higher selenium deposition in eggs than did sodium selenite. 
4.3.  Pigs for fattening 
A study was conducted with a total 80 female pigs (Piétrain   [Large white   Landrace], initial age 11 
weeks, mean bw 25 kg) in two different blocks/periods, each lasting 36 days. Animals were housed in 
pens and allocated to five dietary treatments (four replicates of two pigs).
71 A control unsupplemented 
diet based on barley, wheat, maize, soybeanmeal and cano la (background selenium content   0.11 
mg/kg) was supplemented with 0, 0.1 or 0.3 mg Se/kg feed either from sodium selenite or HMSeBA 
(selenium contents confirmed by analysis). Diets were fed  ad libitum. At the beginning of the trial, 
three days of progressive intake of supplemented diets were allowed as an adaptation period. After 36 
days of feeding experimental diets, pigs were slaughtered and samples of blood for selenium and 
GSH-Px analysis as well as liver for selenium analysis were collected from all animals. 
Although no significant differences were observed in growth performance parameters (mean body 
weight gain 26 kg; mean feed intake 1600 g/day; mean feed/gain ratio 2.21), owing to the short 
duration  of  the  study,  these  performance  data  are  not  further  considered.  Since  there  were  no 
differences  in  parameters  of  selenium  metabolism  between  the  two  experimental  blocks,  the 
cumulated mean values were considered for each parameter. Selenium level and GSH-Px activity in 
plasma were significantly increased in animals supplemented with HMSeBA. At the highest dose of 
selenium from the additive, plasma selenium concentration was higher for HMSeBA treatment than 
for sodium selenite. In liver, selenium concentration was significantly higher in the HMSeBA-treated 
pigs than in pigs receiving either the sodium selenite or the control treatments (Table 6). 
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Table 6:   Effect of feed supplementation (for 36 days) with selenium from sodium selenite or from 
HMSeBA on selenium levels in plasma and liver, and GSH-Px activity in blood of pigs 
for fattening  
Source of Se  Control  Sodium selenite  HMSeBA 
Se supplemented (mg/kg feed  -  0.1  0.3  0.1  0.3 
Se analysed (mg/kg feed)           
Block 1  0.11  0.20  0.38  0.21  0.41 
Block 2  -  -  -  0.21  0.38 
Plasma Se (mg/L)  0.09
a  0.12
b  0.12
b  0.13
b  0.16
c 
Blood GSH-Px activity (U/g Hb)  116
b  135
ab  152
a  146
a  138
a 
Liver Se (mg/kg DM)  1.3
d  1.7
c  1.8
c  2.0
b  2.7
a 
a, b, c, d: Means with different superscript letters within a row are significantly different (P≤ 0.05). 
 
4.4.  Conclusions on efficacy 
The applicant has demonstrated in several studies that HMSeBA is an efficacious source of selenium, 
showing the response in GSH-Px activity. Therefore, the FEEDAP Panel concludes that HMSeBA is 
an efficacious source of selenium for all animal species/categories. The use of the additive in animal 
nutrition does not modify the quality of meat as measured by physico-chemical properties. 
5.  Post-market monitoring 
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
72  and  Good 
Manufacturing Practice 
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
The additive hydroxy-analogue of selenomethionine (HMSeBA) is a safe source of selenium for all 
animal species/categories when used up to maximum authorised total selenium content in complete 
feed.  Considering  the  zootechnical  performance,  haematology  and  biochemistry  as  endpoints  in 
studies on chickens for fattening, turkeys and piglets, a margin of safety of ten was identified. 
Based on a toxicology testing package (acute toxicity, genotoxicity in vitro and in vivo and repeated 
dose toxicity) it is concluded that HMSeBA does not elicit adverse unexpected effects for a selenium 
compound. After being absorbed, HMSeBA is metabolised to Se-Met; consequently, no residues of 
the compound itself occur in animal tissues and products. Compared with inorganic selenium sources, 
the use of HMSeBA in animal nutrition would result in a similar increase in selenium deposition in 
animal  tissues/products  as  that  resulting  from  selenised  yeast.  To  ensure  consumer  safety  from 
consumption  of  food  originating  from  animals  supplemented  with  HMSeBA,  the  FEEDAP  Panel 
concludes that dietary selenium supplementation from the additive should not exceed a maximum of 
0.2 mg Se/kg complete feed.
73  
The additive should be regarded as an eye irritant, but should not be class ified as skin irritant or skin 
sensitiser. Inhalation exposure poses a hazard to users; the FEEDAP Panel concludes, therefore, that 
the formulation and conditions of use of the solid form of the additive should minimise user exposure 
by inhalation. 
                                                       
72   Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down 
requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1. 
73   The maximum total selenium level in animal feeds in the EU is set to 0.5 mg Se/kg complete feed, of which HMSeBA can 
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The use of HMSeBA in feed does not pose an additional risk to the environment, compared with other 
sources  of  selenium  for  which  it  will  substitute,  as  long  as  the  maximum  authorised  content  in 
feedingstuffs is not exceeded. 
HMSeBA  is  an  efficacious  source  of  selenium  for  all  animal  species/categories,  as  it  has  been 
demonstrated in several studies showing the response in GSH-Px activity. The use of the additive in 
animal nutrition does not modify the quality of meat as measured by physico-chemical properties. 
 
RECOMMENDATIONS 
The  ―Description  and  conditions  of  use  of  the  additive  as  proposed  by  the  applicant‖  should  be 
amended as follows: 
-   The trivial name of the additive should be: Hydroxy-analogue of selenomethionine. 
-   The  incorporation  of  the  additive  into  feed  should  be  made  via  premixtures  only;  this 
recommendation concerns both the solid and liquid forms of the product. 
The maximum content for total selenium in feed is set by legislation. The conclusions of the FEEDAP 
Panel on the safety of hydroxy-analogue of selenomethionine for the target animals, the consumer and 
the environment are valid only if these maximum contents are strictly considered in feed formulation 
and feeding practices. Since selenium is routinely supplemented to feed, only a small amount, if any, 
could be administered additionally via water for drinking. Exact dosing in water for drinking can only 
be  achieved  if  the total  dietary  selenium  content  is  known,  which  is  normally  not  the  case. The 
FEEDAP Panel therefore recommends not to use the hydroxy-analogue of selenomethionine via water 
for drinking, also considering the absence of stability data of the additive in water for drinking. 
Exposure of users by inhalation should be avoided. 
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APPENDIX 
Executive Summary of the Evaluation Report of the European Union Reference Laboratory for 
Feed  Additives  on  the  Method(s)  of  Analysis  for  Hydroxy-Methyl-Seleno-Butanoic-Acid 
(HMSeBA)
74 
In  the  current  application  authorisation  is  sought  under  article  4(1)  for  Hydroxy-Methyl-Seleno-
Butanoic-Acid  (HMSeBA),  under  the  category/functional  group  3(b)  ‗nutritional 
additives‘/‗compounds of trace elements‘ according to the classification system of Regulation (EC) 
No 1831/2003. Specifically, authorisation is sought for the use of HMSeBA for all animal species and 
categories. 
The feed additive is a preparation consisting of a minimum of 5 % R,S-2-hydroxy-4 methylseleno 
butanoic  acid  (C5H10O3Se)  and  a  maximum  of  95  %  colloidal  silica  carrier.  The  organo  seleno 
compounds consist of 99 % HMSeBA monomer and 1% dimers; thus corresponding to 40 % total 
selenium in HMSeBA or to 2 % total selenium in the feed additive. The preparation, marketed as a 
liquid or a powder forms, is intended to be incorporated into premixtures, compound feedingstuffs or 
water to obtain a maximum total selenium dosage of 0.25 mg/L water or 0.5 mg/kg feedingstuffs, thus 
complying with legal requirements; no minimum dose was proposed by the Applicant. 
For the determination of HMSeBA in the active substance (HMSeBA per se) and in the feed additive 
(preparation)  the  Applicant  submitted  a  validated  and  further  verified  method,  based  on  High 
Performance Liquid Chromatography coupled to UV detection at 220 nm (HPLC-UV). The following 
performance characteristics were reported:  - a relative standard deviation for repeatability (RSDr) 
ranging from 0.21 to 1.3 %; - a relative standard deviation for intermediate precision (RSDip) ranging 
from 0.83 to 1.3 %; and – a recovery rate (RRec) ranging from 89 to 102 %. Based on the experimental 
evidence  provided  the  EURL  recommends  for  official  control  the  validated  and  further  verified 
gradient HPCL-UV method for the determination of HMSeBA in the active substance and in the feed 
additive. 
For the determination of total selenium in the feed additive and in the active substance the Applicant 
submitted the validated and further verified method developed by the UT2A laboratory  - already 
evaluated and recommended  by  the  EURL  -  based on  microwave  digestion  using  nitric  acid and 
hydrogen peroxide (HNO3/H2O2) followed by inductively coupled plasma mass spectrometry (ICP-
MS), for which the following performance characteristics were reported: - Rrec ranging from 94 to 95 
%; and - RSDip ranging from 1.5 to 2.5 %. However, an alternative method has already been evaluated 
and recommended by the EURL, based on inductively coupled plasma atomic emission spectrometry 
(ICP-AES) for which the following performance characteristics were reported: - Rrec ranging from 99 
to 105 %; - RSDr ranging from 1.1 to 2.7 %; and - RSDip ranging from 1.5 to 2.5 %.  
For the determination of total selenium in premixtures and feedingstuffs the Applicant submitted the 
CEN standard method EN 16159:2012 – already recommended in previous EURL reports - based on 
Hydride  Generation  Atomic  Absorption  Spectrometry  (HGAAS)  after  microwave  digestion  with 
HNO3/H2O2. The following performance characteristics are reported for feed samples: - RSDr ranging 
from 3.4 to 10 %; - a relative standard deviation for reproducibility (RSDR) ranging from 15 to 23 %; 
and - a limit of quantification of 0.125 mg/kg, clearly below the maximum legal limit of 0.5 mg Se/kg 
feed.  For  the  determination  of  total  selenium  in  premixtures,  the  EURL  suggests  diluting  the 
premixtures samples with ground cereal feed and applying the abovementioned HGAAS method. 
The Applicant did not submit any methods for the determination of total selenium in water However, 
the EURL already recommended the method approved by the National Institute for Occupational 
                                                       
74   The full report is available on the EURL website: http://irmm.jrc.ec.europa.eu/SiteCollectionDocuments/FinRep-FAD-
2011-0044.pdf Hydroxy-analogue of selenomethionine (HMSeBA) for all species 
 
EFSA Journal 2013;11(1):3046  28 
Safety and Health (NIOSH) and described in their Manual of Analytical Methods (NMAM), based on 
ICP-AES, for which a limit of detection (LOD) of 0.02 mg/L is reported.  
Further  testing  or  validation  of  the  methods to  be performed  through  the consortium  of  National 
Reference Laboratories as specified by article 10 (Commission Regulation (EC) No 378/2005) is not 
considered necessary. Hydroxy-analogue of selenomethionine (HMSeBA) for all species 
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ABBREVIATIONS 
AP   alkaline phosphatase 
ALT   alanine transaminase 
AST   aspartate transaminase 
bw   body weight 
CFU   colony-forming unit 
CNCM   Collection Nationale de Cultures de Microorganismes  
CV   coefficient of variation 
Cys   cysteine 
CK.  creatine kinase 
DM  dry matter 
DEM  diethoxymethane 
DNA   deoxyribonucleic acid 
EC   European Commission 
EFSA   European Food Safety Authority 
EU   European Union 
EURL  European Union Reference Laboratory 
FEEDAP   EFSA Panel on Additives and Products or Substances used in Animal Feed 
GSH-Px  glutathione peroxidase 
GGT   γ-glutamyltransferase 
GLP   Good Laboratory Practice 
HMSeBA   R,S-2-hydroxy-4-methylselenobutanoic acid 
HPLC   high-performance liquid chromatography 
HCT   haematocrit 
Hb   haemoglobin 
ICP-MS   inductively coupled plasma mass spectrometry 
K   potassium 
LOAEL   lowest observed adverse effect Level 
LOD   limit of detection 
LOQ   limit of euantification 
LD50   lethal dose for 50 % of the population 
LDH   lactate dehydrogenase 
MCV   mean corpuscular volume 
Met   methionine 
MPE   micronucleated polychromatic erythrocyte 
Na   sodium 
NADPH   nicotinamide adenine dinucleotide phosphate 
NE   normochromatic erythrocyte 
NMR   nuclear magnetic resonance 
NCYC   National Collection of Yeast Cultures 
NOAEL   No Observed Adverse Effect Level 
OECD   Organisation for Economic Co-operation and Development  
PCBs   polychlorinated biphenyl 
PE   polychromatic Erythrocyte Hydroxy-analogue of selenomethionine (HMSeBA) for all species 
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RH   relative humidity 
RBC   red blood eell 
Se   selenium 
Se-Cys   selenocysteine 
Se-Met   selenomethionine 
TBARS   thiobarbituric acid-reactive substances 
tBIL   total bilirubin 
TMR   total mixed rations 
TK   thymidine kinase 
UV   vltraviolet 
VICH   Veterinary International Cooperation on Harmonization 
WBC   white blood cell 
 